Therapy Areas: Hereditary Disorders
20 July 2018 - - Lexington, Massachusetts-based pulmonary disease inhaled therapeutics developer Pulmatrix, Inc. (NASDAQ: PULM) has completed all dosing and follow up visits for Part 3 of the ongoing ...
5 July 2018 - - Boston, Massachusetts-based serious disease therapeutics developer Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) has received approval from Health Canada for PrSymdeko (tezacaftor/ivacaft...
18 June 2018 - - Lexington, Massachusetts-based pulmonary disease inhaled therapeutics developer Pulmatrix, Inc. (NASDAQ: PULM) has published data from a dose-ranging Phase 1 clinical study of PUR0200...
24 May 2018 - - US-based RNAi-based therapeutics developer Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has presented new preclinical data on ARO-ENaC, formerly referred to as ARO-Lung1, for the tre...
7 May 2018 - - Durham, NC-based drug discovery company Icagen, Inc. has received an award valued at up to USD 11m from the Bethesda, Maryland-based Cystic Fibrosis (CF) Foundation in support of its re...
1 May 2018 - - Boston, Massachusetts-based serious disease therapeutics developer Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) is initiating two Phase 3 studies of VX-445, tezacaftor, and ivacaftor as a...